Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.
Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for using these for therapeutic benefit: focus on liraglutide.